SLS EBITDA Growth
Sellas Life Sciences Group Inc · EBITDA Growth
SLS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported3.36%period ending
SLS TTM EBITDA YoY % (-32.31% → 3.36%)
Year-over-year change
High-resolution chart · PNG
SLS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 3.355% | |
| 17.5243% | |
| 35.9477% | |
| 41.5768% | |
| 23.7521% | |
| 23.9068% | |
| 16.9464% | |
| 15.1509% | |
| 3.2395% | |
| -1.1605% | |
| 8.9658% | |
| -1.7002% | |
| 5.5364% | |
| -3.7781% | |
| -118.897% | |
| -117.7542% | |
| -158.3162% | |
| -138.4761% | |
| -10.3756% | |
| -33.9702% | |
| -17.4869% | |
| -18.0078% | |
| -37.8649% | |
| -29.3032% | |
| -39.5885% | |
| -12.2303% | |
| -40.813% | |
| 44.1233% | |
| 53.5537% | |
| 43.5294% | |
| 59.1097% | |
| 18.3474% | |
| 17.2758% | |
| 28.7238% | |
| 31.6055% | |
| 31.0843% | |
| 32.2722% | |
| 21.3051% | |
| 8.0528% | |
| 15.8574% | |
| 13.1105% | |
| 26.028% | |
| 30.4526% | |
| 24.4274% | |
| 14.4947% | |
| -19.5151% | |
| -45.8368% | |
| -23.8668% | |
| -18.5583% | |
| -5.0909% | |
| 2.6447% | |
| -87.5814% | |
| -101.936% | |
| -131.7539% | |
| -106.1617% | |
| -47.0888% | |
| -29.8574% | |
| 8.7515% | |
| -1.1062% | |
| 19.5956% | |
| 19.1995% | |
| 7.2874% | |
| 10.3574% | |
| -5.5679% | |
| -10.3791% | |
| -17.4154% | |
| -27.2639% | |
| -29.9833% | |
| -31.6224% | |
| -20.4356% | |
| -21.1933% | |
| -32.3074% |